The safety and efficacy of pertuzumab and trastuzumab combined with investigator selected taxane in first-line treatment of HER2-positive advanced breast cancer were confirmed in the single-arm PERUSE study [16], with the safety profile (which was the primary endpoint) being consistent with earlier study reports (most common grade ≥ 3 adverse event were neutropenia and diarrhea). The gene discussed is ERBB2; the disease is breast cancer.